A pregnant client who is Rh negative asks the nurse how many children they will be able to have before Rh incompatibility causes the fetus to die.
What is the nurse's best response?

Choice A rationale

The constellation of symptoms—localized painful area, redness, and warmth on one breast, accompanied by systemic signs of fever (>38.0°C or 100.4°F) and malaise (general discomfort or uneasiness)—is the classic clinical presentation of mastitis. This condition is typically a bacterial infection (often Staphylococcus aureus) of the breast tissue, commonly occurring 2-4 weeks postpartum, often related to nipple damage or incomplete milk drainage.

Choice B rationale

A plugged milk duct presents as a painful, localized, firm lump or area of fullness in the breast, but it is characteristically not accompanied by systemic signs of fever or malaise. It represents simple mechanical obstruction without the inflammatory response or generalized symptoms indicative of a progressing bacterial infection like mastitis.

Choice C rationale

Unilateral engorgement is highly unlikely at 1 month postpartum; engorgement is common in the immediate postpartum period as milk production first initiates. While it involves a feeling of fullness and firmness, it lacks the intense localized redness, significant pain, and systemic signs (fever, malaise) characteristic of a bacterial infection.

Choice D rationale

A breast yeast infection (candidiasis) typically presents with intense, burning nipple pain that can radiate into the breast, often described as "stabbing," and sometimes a shiny, peeling appearance of the nipple. While it can cause discomfort, the classic presentation usually lacks the pronounced localized area of warmth and redness on the breast tissue itself and the high systemic fever seen in mastitis.

Choice A rationale

Rho(D) immune globulin, or RhoGAM, is an exogenous preparation of anti-D antibodies that bind to any fetal Rh-positive red blood cells that enter the maternal circulation, effectively clearing them before the mother's immune system recognizes the D antigen and mounts an immune response. This prevents sensitization, allowing the woman to have unlimited subsequent Rh-positive children without the risk of developing hemolytic disease of the fetus and newborn (HDFN).

Choice B rationale

The recommendation is not limited to only two children if Rho(D) immune globulin is administered correctly. The medication provides passive immunity to prevent the mother from producing her own anti-D antibodies, which are the cause of HDFN in subsequent Rh-positive fetuses. Administration within 72 hours postpartum and often prophylactically around 28 weeks gestation is standard practice.

Choice C rationale

If Rh sensitization has occurred in a prior pregnancy or due to other exposure and Rho(D) immune globulin was not given, the mother's immune system will have produced anti-D antibodies. These immunoglobulin G (IgG) antibodies can cross the placenta and affect all subsequent Rh-positive fetuses, not just the next one, potentially causing fetal hemolysis and severe anemia.

Choice D rationale

Hemolytic disease of the fetus and newborn (HDFN) is determined by the fetal Rh status, specifically the presence of the D antigen on the fetal red blood cells, which is an autosomal dominant trait. The sex of the fetus (male or female) is genetically unrelated to the inheritance of the Rh factor and does not influence the severity or occurrence of the Rh incompatibility reaction.